Cencora, Inc. $COR Holdings Decreased by State Street Corp

Cencora logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • State Street cut its Cencora stake by 63.4% in the third quarter, selling about 15.9 million shares; it retained 9.2 million shares, or 4.82% of the company.
  • Cencora reported quarterly EPS of $4.66 and revenue of $88.35 billion, beating analyst estimates; revenue rose 5.5% year over year.
  • The company raised its quarterly dividend from $0.60 to $0.66 per share. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $381.
  • Interested in Cencora? Here are five stocks we like better.

State Street Corp lessened its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 63.4% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,203,262 shares of the company's stock after selling 15,926,511 shares during the period. State Street Corp owned 4.82% of Cencora worth $2,763,279,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Elevation Wealth Partners LLC boosted its position in Cencora by 506.2% during the second quarter. Elevation Wealth Partners LLC now owns 97 shares of the company's stock valued at $27,000 after acquiring an additional 81 shares during the last quarter. Meeder Asset Management Inc. grew its holdings in Cencora by 157.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 98 shares of the company's stock worth $29,000 after acquiring an additional 60 shares during the period. Bell Investment Advisors Inc bought a new position in shares of Cencora in the 2nd quarter worth about $28,000. Caitlin John LLC bought a new position in shares of Cencora in the 2nd quarter worth about $28,000. Finally, E Fund Management Hong Kong Co. Ltd. raised its position in shares of Cencora by 192.1% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 111 shares of the company's stock worth $33,000 after acquiring an additional 73 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Stock Performance

Shares of Cencora stock opened at $339.05 on Friday. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54. The firm has a market capitalization of $64.70 billion, a price-to-earnings ratio of 18.92, a PEG ratio of 1.75 and a beta of 0.58. The business has a 50-day simple moving average of $329.42 and a 200 day simple moving average of $316.95. The company has a debt-to-equity ratio of 3.01, a current ratio of 0.94 and a quick ratio of 0.59.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $4.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.58 by $0.08. Cencora had a return on equity of 110.72% and a net margin of 1.03%. The business had revenue of $88.35 billion for the quarter, compared to analyst estimates of $87.95 billion. During the same quarter in the prior year, the company earned $3.84 earnings per share. The company's quarterly revenue was up 5.5% on a year-over-year basis. On average, research analysts anticipate that Cencora, Inc. will post 19.58 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 30th. Investors of record on Friday, November 13th will be issued a $0.66 dividend. The ex-dividend date is Friday, November 13th. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.8%. This is an increase from Cencora's previous quarterly dividend of $0.60. Cencora's dividend payout ratio (DPR) is 14.73%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on COR shares. Wall Street Zen raised Cencora from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Leerink Partners raised their target price on Cencora from $388.00 to $405.00 and gave the stock an "outperform" rating in a research note on Thursday, November 5th. Morgan Stanley lifted their target price on Cencora from $346.00 to $377.00 and gave the stock an "overweight" rating in a report on Friday, October 30th. Robert W. Baird boosted their price target on Cencora from $373.00 to $375.00 and gave the company an "outperform" rating in a research note on Thursday, October 22nd. Finally, Royal Bank Of Canada restated a "sector perform" rating and set a $330.00 price target on shares of Cencora in a report on Tuesday, September 8th. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $381.00.

Read Our Latest Research Report on Cencora

Insider Activity

In related news, EVP Elizabeth Campbell sold 11,300 shares of Cencora stock in a transaction on Monday, August 24th. The shares were sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the sale, the executive vice president owned 19,455 shares of the company's stock, valued at approximately $6,305,754.60. This trade represents a 36.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.38% of the stock is currently owned by corporate insiders.

About Cencora

(Free Report)

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.

See Also

Institutional Ownership by Quarter for Cencora (NYSE:COR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cencora Right Now?

Before you consider Cencora, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.

While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines